BB-031 not checked
Basking Biosciences, Inc. · DTRI-031
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Acute Ischemic Stroke
- Main trialPhase 2
- “The purpose of this study is to evaluate the safety and tolerability of ascending doses (Part A) and selected doses (Part B) of BB-031 in acute ischemic stroke patients presenting within 24 hours of stroke onset. Participants will be randomized to receive one dose of either the investigational drug or placebo and will be followed for 90 days. A total of 228 patients are planned in this study.”In the company’s words, NCT06226805 on ClinicalTrials.gov
- Other names
- DTRI-031
Other drugs for Acute Ischemic Stroke
- Neuroncell-EXCytopeutics Sdn. Bhd. · Phase 2/3
- DM199DiaMedica Therapeutics Inc · Phase 2/3
- SP-8203Shin Poong Pharmaceutical Co. Ltd. · Phase 3
- SHPL-49Shanghai Hutchison Pharmaceuticals Limited · Phase 3
- RhTNK-tPACSPC · Phase 3
- SovateltidePharmazz, Inc. · Phase 3
Coming up1
- Jun 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Jun 2027 | Study of BB-031 in Acute Ischemic Stroke Patients (RAISE) | |
| Phase 1Completed | 19 Apr 2022 | Study of DTRI-031 in Healthy Volunteers | |
| Phase 1Completed | 18 Mar 2026 | Study of BB-025, Alone and After BB-031, in Healthy Volunteers |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026